Nordson (NDSN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 Apr, 2026Executive summary
Achieved record first quarter sales of $669–$669.5 million, up 8.8–9% year-over-year, with 7% organic growth and broad-based segment contributions, especially from Advanced Technology Solutions (ATS) and strong Asia Pacific demand.
Net income rose to $133–$133.4 million, or $2.38 per diluted share, a 40.9–44% increase year-over-year, benefiting from a non-cash gain on a minority technology investment.
Adjusted EPS reached $2.37, up 15% from the prior year, exceeding guidance midpoint.
EBITDA reached a record $203 million, representing 30% of sales, up 8% year-over-year.
Backlog increased approximately 4% year-over-year, supporting a positive outlook.
Financial highlights
Sales reached $669–$669.5 million, a 9% increase from $615–$615.4 million in the prior year; organic sales up 7%.
Adjusted operating profit grew 10–18.1% to $166–$166.4 million; EBITDA margin held steady at 30%.
Net income was $133–$133.4 million, or $2.38 per share; adjusted EPS was $2.37, up from $2.06 last year.
Gross margin was 54.7%, nearly flat compared to the prior year.
Free cash flow was $122.9–$123 million, with a conversion rate of 105% for the third consecutive quarter.
Outlook and guidance
Q2 sales expected between $710 million and $740 million; adjusted EPS forecasted at $2.70–$2.90.
Full-year sales guidance raised to $2.86–$2.98 billion, with adjusted EPS guidance increased to $11–$11.60.
Guidance assumes continued electronics momentum, modest improvement in industrial and automotive, and is supported by increased backlog and order entry momentum.
Full-year adjusted EPS expected to grow 7–13%, with midpoint at $11.30.
Latest events from Nordson
- Q1 2026 sales rose 9% with raised full-year outlook and strong cash flow conversion.NDSN
Investor presentation26 Mar 2026 - Strong growth, innovation, and cash flow support 6-8% annual revenue growth through 2029.NDSN
Investor presentation19 Feb 2026 - Q3 sales up 2% to $662M; Atrion acquisition expands medical segment; guidance raised.NDSN
Q3 202423 Jan 2026 - 2025–2029 targets 6%-8% revenue and 10%-12% EPS growth, driven by strategy and portfolio evolution.NDSN
Investor Day 202420 Jan 2026 - Shareholders will vote on directors, auditor ratification, and executive pay amid record results and strong governance.NDSN
Proxy Filing16 Jan 2026 - Annual meeting to elect directors, ratify auditor, and approve executive pay, all board-recommended.NDSN
Proxy Filing16 Jan 2026 - Record sales and EBITDA in 2024; 2025 outlook targets growth, led by Atrion amid macro uncertainty.NDSN
Q4 202411 Jan 2026 - Sales fell 2.8% but backlog surged 15%, signaling growth potential for 2025.NDSN
Q1 20258 Jan 2026 - Record sales, strong margins, and robust cash flow set up for solid growth in 2026.NDSN
Q4 202512 Dec 2025